Exact Sciences Corporation

431 articles with Exact Sciences Corporation

• Exact Sciences Licenses Targeted Digital Sequencing Method to Extend Leadership in Precision Oncology

  1/13/2021

  Worldwide Exclusive License Provides Access to Targeted Digital Sequencing (TARDIS) Blood Biopsy Method for Use in Minimal Residual Disease Testing

• New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®

  1/12/2021

  Cologuard's high specificity would help minimize risk and cost from unnecessary diagnostic procedures in this age group

• Exact Sciences Announces Preliminary Fourth Quarter 2020 Results

  1/11/2021

  Expected total revenue of $464.5-467.5M, including Screening revenue of $249-250M, Precision Oncology revenue of $117-118M, and COVID-19 testing revenue of $98.5-99.5M

• Exact Sciences to participate in J.P. Morgan Healthcare Conference - Dec 28, 2020

  12/28/2020

  Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences to participate in December 2020 investor conference

  11/23/2020

  Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.

• Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)

  11/17/2020

  Consortium aims to make comprehensive genomic profiling accessible to advanced cancer patients in the U.S. to inform medical management and improve patient outcomes.

• Exact Sciences to participate in November 2020 investor conferences

  11/2/2020

  Exact Sciences Corp. announced that company management will participate in the following conferences and invited investors to participate by webcast.

• Exact Sciences Announces Entry into Agreements to Sell $869 Million of Common Stock in Registered Direct Offering

  10/27/2020

  Exact Sciences Corporation announced the entry into agreements to sell an aggregate of 8,605,483 shares of its common stock, par value $0.01 per share, in a registered direct offering to ten institutional investors, including some of its largest shareholders as well as healthcare specialist firms Casdin Capital and Rock Springs Capital.

• Exact Sciences To Acquire Thrive Earlier Detection, Becoming A Leader In Blood-Based, Multi-Cancer Screening

  10/27/2020

  Brings Together Cancer Screening R&D Pioneers to Transform the Future of Cancer Diagnostics and Impact Lives

• Exact Sciences Announces Third Quarter 2020 Results

  10/27/2020

  Exact Sciences Corp. announced that the company generated revenue of $408.4 million for the third quarter ended September 30, 2020, compared to $218.8 million for the same period of 2019.

• 

  Exact Sciences to Acquire Thrive in Deal Valued at $2.15 Billion

  10/27/2020

  The deal, which is worth up to $2.15 billion, is expected to close in the first quarter of 2021 and is subject to regulatory approval.

• Exact Sciences Selects Veeva Vault Clinical Suite to Help Accelerate Innovation

  10/14/2020

  Veeva Systems announced that Exact Sciences, a leading provider of cancer screening and diagnostic tests, selected Veeva Vault Clinical Suite to design and run its clinical studies.

• Exact Sciences Introduces the Oncotype MAP™ Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer

  10/12/2020

  Exact Sciences Corp. (NASDAQ: EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, refractory, or  recurrent cancer. The Oncotype

• Exact Sciences schedules third quarter 2020 earnings call

  10/9/2020

  Exact Sciences Corp. announced that the company plans to release its third quarter 2020 financial results after the close of the U.S. financial markets on October 29, 2020.

• Exact Sciences and Pfizer Extend and Amend Cologuard® Promotion Agreement

  10/7/2020

  Exact Sciences Corp. and Pfizer Inc. announced an extension and amendment of their agreement to promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer.

• Exact Sciences to participate in Cowen Liquid Biopsy Summit

  9/17/2020

  Exact Sciences Corp. announced that company management will participate in the following event and invited investors to participate by webcast.

• Exact Sciences to participate in September investor conference - Sep 01, 2020

  9/1/2020

  Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences to participate in August 2020 investor conference

  8/3/2020

  Exact Sciences Corp. announced that company management will participate in the following conference and invited investors to participate by webcast.

• Exact Sciences schedules annual meeting, second quarter 2020 earnings call

  7/8/2020

  Exact Sciences Corp. announced that the company has scheduled its virtual annual stockholders meeting and second quarter 2020 earnings call.

• Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients

  6/16/2020

  Findings, published in Urology, suggest that GPS™ results can help guide the intensity of clinical management in this higher-risk patient population